AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Recruiting · Not applicable · NCT06959524
Conditions: Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries
At a glance
- Research payments reported, 2025
- $219,872
- U.S. investigators named
- 10
- Sites paid
- 10
- Planned or actual enrollment
- 1,616
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- Drug Eluting Balloon (device), Drug eluting stent (device), Plain old balloon angioplasty (procedure)
- Dates
- Started 2025-08-21; completion 2032-03
- Results posted
- Not yet
AGENT DCB STANCE is a prospective, multicenter, open-label, 1:1 randomized controlled study designed to assess the safety and effectiveness of a treatment strategy with the AGENT Drug-Coated Balloon compared to standard of care percutaneous coronary intervention (PCI) treatment with drug eluting stent (DES) and/or balloon angioplasty in patients with de novo coronary lesions. Subjects must have a de novo target lesion located in a native coronary artery.
From ClinicalTrials.gov, last updated 2026-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $219,872 in research payments for this study in 2025 (26 payments).
Products named: Clinical Trial Product
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jubin P. Joseph, MD PHD Interventional Cardiology · Los Angeles, CA
- Cinthia T. Bateman, M.D. Interventional Cardiology · Littleton, CO
- David A. Brogno, M.D. Interventional Cardiology · Suffern, NY
- Yumiko Kanei, M.D. Interventional Cardiology · Bronx, NY
- Amar Krishnaswamy, M.D. Interventional Cardiology · Cleveland, OH
- Torrey R. Schmidt, DO Cardiology · Wormleysburg, PA
- Jorge A. Alvarez, MD Interventional Cardiology · San Antonio, TX
- Alpesh R. Shah, M.D. Interventional Cardiology · Pearland, TX
- Robert Stoler, M.D. Interventional Cardiology · Dallas, TX
- Angela M. Taylor, M.D. Interventional Cardiology · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Baylor Research Institute $69,350
- HCA Research Institute LLC $28,203
- Biomedical Research Alliance of New York $27,320
- Trustees of Columbia Univ in The City of Ny $21,702
- Cleveland Clinic, OH $21,665
- University of Southern California $18,226
- The Methodist Hospital Research Institute $13,058
- Pinnacle Health Cardiovascular Institute $10,423
- Portercare Adventist Health System $7,750
- University of Virginia Medical Center, VA $2,176
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.